|
1
|
Shirazi HA, Hedayati M, Daneshpour MS,
Shafiee A and Azizi F: Analysis of loss of heterozygosity effect on
thyroid tumor with oxyphilia cell locus in familial non medullary
thyroid carcinoma in Iranian families. Indian J Hum Genet.
18:340–343. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Patel KN and Shaha AR: Poorly
differentiated and anaplastic thyroid cancer. Cancer Control.
13:119–128. 2006.PubMed/NCBI
|
|
3
|
Fassnacht M, Kreissl MC, Weismann D and
Allolio B: New targets and therapeutic approaches for endocrine
malignancies. Pharmacol Ther. 123:117–141. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ghossein R: Problems and controversies in
the histopathology of thyroid carcinomas of follicular cell origin.
Arch Pathol Lab Med. 133:683–691. 2009.PubMed/NCBI
|
|
5
|
Hedayati M, Zarif Yeganeh M, Sheikhol
Eslami S, Rezghi Barez S, Hoghooghi Rad L and Azizi F: Predominant
RET germline mutations in exons 10, 11, and 16 in Iranian patients
with hereditary medullary thyroid carcinoma. J Thyroid Res.
2011:2642482011.PubMed/NCBI
|
|
6
|
Kondo T, Ezzat S and Asa SL: Pathogenetic
mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer.
6:292–306. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Xing M: BRAF mutation in thyroid cancer.
Endocr Relat Cancer. 12:245–262. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Vasko V, Ferrand M, Di Cristofaro J,
Carayon P, Henry JF and de Micco C: Specific pattern of RAS
oncogene mutations in follicular thyroid tumors. J Clin Endocrinol
Metab. 88:2745–2752. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hedayati M, Nabipour I, Rezaei-Ghaleh N
and Azizi F: Germline RET mutations in exons 10 and 11: an Iranian
survey of 57 medullary thyroid carcinoma cases. Med J Malaysia.
61:564–569. 2006.PubMed/NCBI
|
|
10
|
Nikiforov YE: RET/PTC rearrangement in
thyroid tumors. Endocr Pathol. 13:3–16. 2002. View Article : Google Scholar
|
|
11
|
Bethanis S, Koutsodontis G, Palouka T, et
al: A newly detected mutation of the RET protooncogene in exon 8 as
a cause of multiple endocrine neoplasia type 2A. Hormones (Athens).
6:152–156. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lips CJ, Hӧppener JW and Thijssen JH:
Medullary thyroid carcinoma: role of genetic testing and calcitonin
measurement. Ann Clin Biochem. 38:168–179. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Musholt TJ, Schӧnefeld S, Schwarz CH, et
al: Impact of pathognomonic genetic alterations on the prognosis of
papillary thyroid carcinoma. ESES vienna presentation. Langenbecks
Arch Surg. 395:877–883. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kimura ET, Nikiforova MN, Zhu Z, Knauf JA,
Nikiforov YE and Fagin JA: High prevalence of BRAF mutations in
thyroid cancer: genetic evidence for constitutive activation of the
RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma.
Cancer Res. 63:1454–1457. 2003.PubMed/NCBI
|
|
15
|
Nikiforova MN, Kimura ET, Gandhi M, et al:
BRAF mutations in thyroid tumors are restricted to papillary
carcinomas and anaplastic or poorly differentiated carcinomas
arising from papillary carcinomas. J Clin Endocrinol Metab.
88:5399–5404. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sharma S, Kelly TK and Jones PA:
Epigenetics in cancer. Carcinogenesis. 31:27–36. 2010. View Article : Google Scholar
|
|
17
|
Egger G, Liang G, Aparicio A and Jones PA:
Epigenetics in human disease and prospects for epigenetic therapy.
Nature. 429:457–463. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Katz TA, Huang Y, Davidson NE and
Jankowitz RC: Epigenetic reprogramming in breast cancer: from new
targets to new therapies. Ann Med. 24:1–12. 2014.PubMed/NCBI
|
|
19
|
Kondo T, Nakazawa T, Ma D, et al:
Epigenetic silencing of TTF-1/NKX2,1 through DNA hypermethylation
and histon H3 modification in thyroid carcinoma. Lab invest.
89:791–799. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Moon JW, Lee SK, Lee JO, et al:
Identification of novel hypermethylated genes and demethylationg
effect of vincristine in colorectal cancer. J Exp Clin Cancer Res.
33:42014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jones PA and Baylin SB: The epigenomics of
cancer. Cell. 128:683–692. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Herman JG and Baylin SB: Gene silencing in
cancer in association with promoter hypermethylation. N Engl J Med.
349:2042–2054. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Eden A, Gaudet F, Waghmare A and Jaenisch
R: Chromosomal instability and tumors promoted by DNA
hypomethylation. Science. 300:4552003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lu J, Getz G, Miska EA, et al: MicroRNA
expression profiles classify human cancers. Nature. 435:834–838.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cantley LC and Neel BG: New insights into
tumor suppression: PTEN suppresses tumor formation by restraining
the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA.
96:4240–4245. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chu EC and Tarnawski AS: PTEN regulatory
functions in tumor suppression and cell biology. Med Sci Monit.
10:RA235–RA241. 2004.PubMed/NCBI
|
|
27
|
Alvarez-Nuñez F, Bussaglia E, Mauricio D,
et al Thyroid Neoplasia Study Group: PTEN promoter methylation in
sporadic thyroid carcinomas. Thyroid. 16:17–23. 2006.PubMed/NCBI
|
|
28
|
Pfeifer GP and Dammann R: Methylation of
the tumor suppressor gene RASSF1A in human tumors. Biochemistry
(Mosc). 70:576–583. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Schagdarsurengin U, Gimm O, Hoang-Vu C,
Dralle H, Pfeifer GP and Dammann R: Frequent epigenetic silencing
of the CpG island promoter of RASSF1A in thyroid carcinoma. Cancer
Res. 62:3698–3701. 2002.PubMed/NCBI
|
|
30
|
Xing M, Cohen Y, Mambo E, et al: Early
occurrence of RASSF1A hypermethylation and its mutual exclusion
with BRAF mutation in thyroid tumorigenesis. Cancer Res.
64:1664–1668. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Qi JH, Ebrahem Q, Moore N, et al: A novel
function for tissue inhibitor of metalloproteinases-3 (TIMP3):
inhibition of angiogenesis by blockage of VEGF binding to VEGF
receptor-2. Nat Med. 9:407–415. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hoque MO, Rosenbaum E, Westra WH, et al:
Quantitative assessment of promoter methylation profiles in thyroid
neoplasms. J Clin Endocrinol Metab. 90:4011–4018. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hu S, Liu D, Tufano RP, et al: Association
of aberrant methylation of tumor suppressor genes with tumor
aggressiveness and BRAF mutation in papillary thyroid cancer. Int J
Cancer. 119:2322–2329. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
De Falco V, Castellone MD, De Vita G, et
al: RET/papillary thyroid carcinoma oncogenic signaling through the
Rap1 small GTPase. Cancer Res. 67:381–390. 2007.
|
|
35
|
Gao L, Feng Y, Bowers R, et al:
Ras-associated protein-1 regulates extracellular signal-regulated
kinase activation and migration in melanoma cells: two processes
important to melanoma tumorigenesis and metastasis. Cancer Res.
66:7880–7888. 2006. View Article : Google Scholar
|
|
36
|
Wang Z, Dillon TJ, Pokala V, et al:
Rap1-mediated activation of extracellular signal-regulated kinases
by cyclic AMP is dependent on the mode of Rap1 activation. Mol Cell
Biol. 26:2130–2145. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhang L, Chenwei L, Mahmood R, et al:
Identification of a putative tumor suppressor gene Rap1GAP in
pancreatic cancer. Cancer Res. 66:898–906. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhang Z, Mitra RS, Henson BS, et al:
Rap1GAP inhibits tumor growth in oropharyngeal squamous cell
carcinoma. Am J Pathol. 168:585–596. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Nellore A, Paziana K, Ma C, et al: Loss of
Rap1GAP in papillary thyroid cancer. J Clin Endocrinol Metab.
94:1026–1032. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Tsygankova OM, Prendergast GV, Puttaswamy
K, et al: Downregulation of Rap1GAP contributes to Ras
transformation. Mol Cell Biol. 27:6647–6658. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Rodríguez-Rodero S, Fernández AF,
Fernández-Morera JL, et al: DNA methylation signatures identify
biologically distinct thyroid cancer subtypes. J Clin Endocrinol
Metab. 98:2811–2821. 2013.PubMed/NCBI
|
|
42
|
Ogasawara S, Maesawa C, Yamamoto M, et al:
Disruption of cell-type-specific methylation at the Maspin gene
promoter is frequently involved in undifferentiated thyroid
cancers. Oncogene. 23:1117–1124. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Xing M, Usadel H, Cohen Y, et al:
Methylation of the thyroid-stimulating hormone receptor gene in
epithelial thyroid tumors: a marker of malignancy and a cause of
gene silencing. Cancer Res. 63:2316–2321. 2003.PubMed/NCBI
|
|
44
|
Faam B, Daneshpour MS, Azizi F, Salehi M
and Hedayati M: Association between TPO gene polymorphisms and
anti-TPO level in Tehranian population: TLGS. Gene. 498:116–119.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Eze OP, Starker LF and Carling T: The role
of epigenetic alterations in papillary thyroid carcinogenesis. J
Thyroid Res 2011: 895470. 2011.PubMed/NCBI
|
|
46
|
Xing M: Gene methylation in thyroid
tumorigenesis. Endocrinology. 148:948–953. 2007. View Article : Google Scholar
|
|
47
|
He H, Jazdzewski K, Li W, et al: The role
of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad
Sci USA. 102:19075–19080. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Kitamura Y and Hirotab S: Kit as a human
oncogenic tyrosine kinase. Cell Mol Life Sci. 61:2924–2931. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Weber F, Teresi RE, Broelsch CE, Frilling
A and Eng C: A limited set of human MicroRNA is deregulated in
follicular thyroid carcinoma. J Clin Endocrinol Metab.
91:3584–3591. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Gallagher WM, Greene LM, Ryan MP, et al:
Human fibulin-4: analysis of its biosynthetic processing and mRNA
expression in normal and tumour tissues. FEBS Lett. 489:59–66.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Schulte KM, Jonas C, Krebs R and Rӧher HD:
Activin A and activin receptors in thyroid cancer. Thyroid.
11:3–14. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Abraham D, Jackson N, Gundara JS, et al:
MicroRNA profiling of sporadic and hereditary medullary thyroid
cancer identifies predictors of nodal metastasis, prognosis, and
potential therapeutic targets. Clin Cancer Res. 17:4772–4781. 2011.
View Article : Google Scholar
|
|
53
|
Mian C, Pennelli G, Fassan M, et al:
MicroRNA profiles in familial and sporadic medullary thyroid
carcinoma: preliminary relationships with RET status and outcome.
Thyroid. 22:890–896. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Lagos-Quintana M, Rauhut R, Lendeckel W
and Tuschl T: Identification of novel genes coding for small
expressed RNAs. Science. 294:853–858. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Frezzetti D, De Menna M, Zoppoli P, et al:
Upregulation of miR-21 by Ras in vivo and its role in tumor growth.
Oncogene. 30:275–286. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Zuo H, Gandhi M, Edreira MM, et al:
Downregulation of Rap1GAP through epigenetic silencing and loss of
heterozygosity promotes invasion and progression of thyroid tumors.
Cancer Res. 70:1389–1397. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Stephen JK, Chitale D, Narra V, Chen K M,
Sawhney R and Worsham MJ: DNA methylation in thyroid tumorigenesis.
Cancers (Basel). 3:1732–1743. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Zhang X, Li D, Li M, et al: MicroRNA-146a
targets PRKCE to modulate papillary thyroid tumor development. Int
J Cancer. 134:257–267. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Visone R, Russo L, Pallante P, et al:
MicroRNAs (miR)-221 and miR-222, both overexpressed in human
thyroid papillary carcinomas, regulate p27Kip1 protein levels and
cell cycle. Endocr Relat Cancer. 14:791–798. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Meng F, Henson R, Wehbe-Janek H, Ghoshal
K, Jacob ST and Patel T: MicroRNA-21 regulates expression of the
PTEN tumor suppressor gene in human hepatocellular cancer.
Gastroenterology. 133:647–658. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Asangani IA, Rasheed SA, Nikolova DA, et
al: MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor
suppressor Pdcd4 and stimulates invasion, intravasation and
metastasis in colorectal cancer. Oncogene. 27:2128–2136. 2008.
View Article : Google Scholar
|
|
62
|
Sabatel C, Malvaux L, Bovy N, et al:
MicroRNA-21 exhibits antiangiogenic function by targeting RhoB
expression in endothelial cells. PLoS One. 6:e169792011. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Jazdzewski K, Boguslawska J, Jendrzejewski
J, et al: Thyroid hormone receptor beta (THRB) is a major target
gene for microRNAs deregulated in papillary thyroid carcinoma
(PTC). J Clin Endocrinol Metab. 96:E546–E553. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Sun Y, Yu S, Liu Y, Wang F, Liu Y and Xiao
H: Expression of miRNAs in papillary thyroid carcinomas is
associated with BRAF mutation and clinicopathological features in
Chinese patients. Int J Endocrinol 2013: 128735. 2013.PubMed/NCBI
|
|
65
|
Marini F, Luzi E and Brandi ML: MicroRNA
role in thyroid cancer development. J Thyroid Res 2011: 407123.
2011.
|
|
66
|
Hudson J, Duncavage E, Tamburrino A, et
al: Overexpression of miR-10a and miR-375 and downregulation of
YAP1 in medullary thyroid carcinoma. Exp Mol Pathol. 95:62–67.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Ajith TA: Physiological relevance and
theraeutic value of micro RNA in cancer. Front Pathol Genet.
1:15–19. 2013.
|
|
68
|
Chen J, Wang M, Guo M, Xie Y and Cong YS:
miR-127 regulates cell proliferation and senescence by targeting
BCL6. PLoS One. 8:e802662013. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Cahill S, Smyth P, Denning K, et al:
Effect of BRAFV600E mutation on transcription and
post-transcriptional regulation in a papillary thyroid carcinoma
model. Mol Cancer. 6:212007. View Article : Google Scholar : PubMed/NCBI
|
